At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 80 target
Drug / intervention
DCX +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating DCX and surgery for Stage II and III Esophageal Squamous Cell Carcinoma. Targeting 80 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether docetaxel, cisplatin, and capecitabine (DCX) are effective as the neoadjuvant chemotherapy before esophagectomy in patients with loco-regional esophageal squamous cell carcinoma (ESCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionOct 2018
TodayJul 2026
First PostedSep 27, 2016
Enrollment StartOct 1, 2016
Primary CompletionOct 1, 2018
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 9.8 years ago
Interventions
DCXdrug
docetaxel, cisplatin and capecitabine
surgeryprocedure
Ivor Lewis Esophagectomy